WallStSmart

Clene Inc. (CLNN)vsMcCormick & Company Incorporated (MKC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McCormick & Company Incorporated generates 5304900% more annual revenue ($7.11B vs $134,000). MKC leads profitability with a 23.1% profit margin vs 0.0%. MKC earns a higher WallStSmart Score of 80/100 (A-).

CLNN

Avoid

22

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: -28.11

MKC

Exceptional Buy

80

out of 100

Grade: A-

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.58
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CLNN.

MKCUndervalued (+25.2%)

Margin of Safety

+25.2%

Fair Value

$94.33

Current Price

$47.24

$47.09 discount

UndervaluedFair: $94.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLNN2 strengths · Avg: 10.0/10
EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Debt/EquityHealth
-1.1710/10

Conservative balance sheet, low leverage

MKC6 strengths · Avg: 9.0/10
P/E RatioValuation
8.0x10/10

Attractively priced relative to earnings

EPS GrowthGrowth
528.0%10/10

Earnings expanding 528.0% YoY

Return on EquityProfitability
23.5%9/10

Every $100 of equity generates 24 in profit

Profit MarginProfitability
23.1%9/10

Keeps 23 of every $100 in revenue as profit

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

CLNN4 concerns · Avg: 2.8/10
Market CapQuality
$74.37M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1738.0%2/10

ROE of -1738.0% — below average capital efficiency

MKC2 concerns · Avg: 4.0/10
PEG RatioValuation
1.884/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CLNN

The strongest argument for CLNN centers on EPS Growth, Debt/Equity.

Bull Case : MKC

The strongest argument for MKC centers on P/E Ratio, EPS Growth, Return on Equity. Profitability is solid with margins at 23.1% and operating margin at 14.3%. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : CLNN

The primary concerns for CLNN are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : MKC

The primary concerns for MKC are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

CLNN profiles as a value stock while MKC is a growth play — different risk/reward profiles.

CLNN carries more volatility with a beta of 0.92 — expect wider price swings.

MKC is growing revenue faster at 16.7% — sustainability is the question.

MKC generates stronger free cash flow (18M), providing more financial flexibility.

Bottom Line

MKC scores higher overall (80/100 vs 22/100), backed by strong 23.1% margins and 16.7% revenue growth. Both earn "Exceptional Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Clene Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.

McCormick & Company Incorporated

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

McCormick & Company is an American multinational food company that manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavoring products to retail outlets, food manufacturers, and foodservice businesses.

Want to dig deeper into these stocks?